ArticleCNS neuroscience & therapeutics2026
PACAP Alleviates Paclitaxel-Induced Peripheral Neuropathy by Targeting Oxidative Stress and Mitochondrial Damage via the PGC-1α Pathway.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Norepinephrine regulates hippocampal mitochondrial biogenesis via β2-adrenergic receptor signaling and PGC-1α.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Pituitary adenylate cyclase-activating polypeptide and mitochondrial homeostasis in neuronal injury: mechanisms and translational prospects.Frontiers in immunology · 2026Review
- PACAP Alleviates Paclitaxel-Induced Peripheral Neuropathy by Targeting Oxidative Stress and Mitochondrial Damage via the PGC-1α Pathway.CNS neuroscience & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPaclitaxel-induced peripheral neuropathy (PIPN) is a severe and dose-limiting side effect. This study investigated the therapeutic potential of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) and its underlying mechanism.
methodsA murine PIPN model was established. Behavioral tests assessed neuropathic pain. Molecular and cellular analyzes, including western blot, ELISA, and transmission electron microscopy, evaluated oxidative stress, mitochondrial function, and key protein expression in dorsal root ganglia (DRG) and SH-SY5Y cells. The PGC-1α inhibitor SR-18292 was used for mechanistic validation.
resultsHigh-dose PACAP (100 μg/kg) significantly alleviated PTX-induced mechanical allodynia and thermal/cold hyperalgesia. It reduced oxidative stress (lowered ROS/MDA, increased SOD) and restored mitochondrial function (improved membrane potential, ATP, and ultrastructure) in DRG neurons. PACAP upregulated PGC-1α and HO-1 expression, and its protective effects were abolished by PGC-1α inhibition. Crucially, PACAP did not interfere with PTX's antitumor efficacy.
conclusionPACAP alleviates PIPN by activating the PGC-1α pathway to improve mitochondrial function and counteract oxidative stress, presenting a promising adjunct therapy that does not compromise chemotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.